Ligand Pharmaceuticals Incorporated (LGND) Stock Analysis & Winston Score

Ligand Pharmaceuticals is a biotech company that doesn't make drugs itself — instead, it owns a large portfolio of drug royalties and licenses that it rents out to other pharmaceutical companies. When those partner companies sell their drugs, Ligand collects a cut of the revenue. Its most well-known technology platform is called Captisol, a chemical ingredient that helps make drugs safer and easier to dissolve, and it is used in several approved medicines including treatments for COVID-19 and blood cancer. Ligand earns money primarily through royalties, milestone payments, and licensing fees — not by selling products directly to patients. This model keeps costs extremely low, which explains its near-100% gross margin. The company operates mainly in the United States but has partners selling drugs globally, giving it broad international exposure. Its main competitive advantage is its large, diversified royalty portfolio, which reduces dependence on any single drug. The key risk is that royalty revenue can drop sharply if a partner drug loses market share or faces generic competition.